Impaired host response and HCV disturbance of type I/III IFN signaling are closely associated with non-response to IFN-based anti-HCV treatment

• Project/Area Number: 24590960
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: Tokyo Medical and Dental University
• Principal Investigator: OOKA Shinya 東京医科歯科大学, 医歯(薬)学総合研究科, 特任准教授 (90361691)
• Co-Investigator(Kenkyū-buntansha): ASAHINA Yasuhiro 東京医科歯科大学, 大学院医歯学総合研究科, 寄附講座教授 (00422692) ; WATANABE Mamoru 東京医科歯科大学, 大学院医歯学総合研究科, 教授 (10175127)
• Co-Investigator(Renkei-kenkyūsha): SAKAMOTO Naoya 北海道大学, 医学研究科, 教授 (10334418)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000); Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
• Keywords: ＨＣＶ / インターフェロン / ＮＳ4Ｂ / ＩＬ28Ｂ / HCV / Cardif / IFNλ / IL-6

Outline of Final Research Achievements

HCV infection blocks cellular IFN-mediated antiviral signaling through cleavage of Cardif by HCV-NS3/4A serine protease. Like NS3/4A, we found NS4B protein strongly blocks IFN-β production signaling mediated by RIG-I. IFN-β promoter reporter assay showed that IFN-β promoter activation induced by RIG-I or Cardif was significantly suppressed by both NS4B and NS3/4A, whereas STING-induced IFN-β activation was suppressed by NS4B but not by NS3/4A, suggesting that NS4B had a distinct point of interaction. Immunoprecipitation and bimolecular fluorescence complementation (BiFC) assays demonstrated that NS4B specifically bound STING. Therefore, NS4B suppresses RIG-I-mediated IFN-β production signaling through a direct protein interaction with STING. Moreover, we reported over-expression of IL6, which is inhibitory molecule of type I/III IFN signaling, and IL28B (type III IFN) SNPs were closely associated with non-response to IFN-based anti-HCV therapy.

Research Products

• [Journal Article] Impaired induction of IL28B and expression of IFNλ4 associated with non-response to interferon-based therapy in chronic hepatitis C. (2015)
  • Author(s): Murakawa M, Asahina Y, Nakagawa M, Sakamoto N, Nitta S, Kusano-Kitazume A, Watanabe T, Kawai-Kitahata F, Otani S, Taniguchi M, Goto F, Nishimura-Sakurai Y, Itsui Y, Azuma S, Kakinuma S, Watanabe M
  • Journal Title: J Gastroenterol Hepatol Volume: 印刷中 Issue: 6 Pages: 1075-84
  • DOI: 10.1111/jgh.12902
  • Peer Reviewed / Open Access
• [Journal Article] Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions. (2015)
  • Author(s): Suda G, Yamamoto Y, Nagasaka A, Furuya K, Kudo M, Chuganji Y, Tsukuda Y, Tsunematsu S, Sato F, Terasita K, Nakai M, Horimoto H, Sho T, Natsuizaka M, Ogawa K, Ohnishi S, Chuma M, Fujita Y, Abe R, Taniguchi M, Nakagawa M, Asahina Y, Sakamoto N
  • Journal Title: Hepatol Res Volume: 印刷中 Issue: 8 Pages: 837-45
  • DOI: 10.1111/hepr.12421
  • NAID: 120005820706
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] Hepatocellular carcinoma risk assessment using gadoxetic acid-enhanced hepatocyte phase magnetic resonance imaging. (2015)
  • Author(s): Komatsu N, Motosugi U, Maekawa S, Shindo K, Sakamoto M, Sato M, Tatsumi A, Miura M, Amemiya F, Nakayama Y, Inoue T, Fukasawa M, Uetake T, Ohtaka M, Sato T, Asahina Y, Kurosaki M, Izumi N, Ichikawa T, Araki T, Enomoto N.
  • Journal Title: Hepatol Res Volume: - Issue: 13 Pages: 1339-1346
  • DOI: 10.1111/hepr.12309
  • Peer Reviewed
• [Journal Article] Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early stage hepatocellular carcinoma. (2014)
  • Author(s): Tsuchiya K, Asahina Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Kurosaki M, Enomoto N, Izumi N.
  • Journal Title: Liver Transpl Volume: 20 Pages: 291-297
  • Peer Reviewed / Acknowledgement Compliant
• [Journal Article] Reduced organic anion transporter expression is a risk factor for hepatocellular carcinoma in chronic hepatitis C patients. (2014)
  • Author(s): Yasui Y, Kudo A, Kurosaki M, Matsuda S, Muraoka M, Tamaki N, Suzuki S, Hosokawa T, Ueda K, Matsunaga K, Nakanishi H, Tsuchiya K, Itakura J, Takahashi Y, Tanaka S, Asahina Y, Enomoto N, Arii S, Izumi N.
  • Journal Title: Oncology Volume: 86(1) Issue: 1 Pages: 53-62
  • DOI: 10.1159/000356643
  • Peer Reviewed
• [Journal Article] New susceptibility and resistance HLA-DP alleles to HBV-related diseases identified by a trans-ethnic association study in Asia. (2014)
  • Author(s): Nishida N, Sawai H, Kashiwase K, Minami M, Sugiyama M, Seto WK, Yuen MF, Posuwan N, Poovorawan Y, Ahn SH, Han KH, Matsuura K, Tanaka Y, Kurosaki M, Asahina Y, Izumi N, Kang JK, （省略）, Tokunaga K, and Mizokami M
  • Journal Title: PLoS One Volume: 9 Issue: 2 Pages: e86449-e86449
  • DOI: 10.1371/journal.pone.0086449
  • Peer Reviewed / Open Access
• [Journal Article] Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients. (2014)
  • Author(s): Tamaki N, Kurosaki M, Matsuda S, Nakata T, Muraoka M, Suzuki Y, Yasui Y, Suzuki S, Hosokawa T, Nishimura T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Matsunaga K, Taki K, Asahina Y, Izumi N.
  • Journal Title: Hepatol Res Volume: 44 Issue: 7 Pages: 720-727
  • DOI: 10.1111/hepr.12179
  • Peer Reviewed
• [Journal Article] JSH guidelines for the management of hepatitis B virus infection. (2014)
  • Author(s): Asahina Y, HayashinN, Hiramatsu N, Izumi N, Koike K, Kumada H, Kurosaki M, Oketani M, Suzuki F, Takikawa H, Tanaka A, Tanaka E, Tanaka Y, Tsubouchi H, Yotsuyanagi H.
  • Journal Title: Hepatol Res Volume: 44 Issue: S1 Pages: 1-58
  • DOI: 10.1111/hepr.12269
  • Peer Reviewed
• [Journal Article] JSH guidelines for the management of hepatitis C virus infection: a 2014 update for genotype 1. (2014)
  • Author(s): Asahina Y, HayashinN, Hiramatsu N, Izumi N, Koike K, Kumada H, Kurosaki M, Oketani M, Suzuki F, Takikawa H, Tanaka A, Tanaka E, Tanaka Y, Tsubouchi H, Yotsuyanagi H.
  • Journal Title: Hepatol Res Volume: 44 Issue: S1 Pages: 59-70
  • DOI: 10.1111/hepr.12272
  • Peer Reviewed
• [Journal Article] Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. (2013)
  • Author(s): Tsuchiya K, Asahina Y, Matsuda S, Muraoka M, Nakata T, Suzuki Y, Tamaki N, Yasui Y, Suzuki S, Hosokawa T, Nishimura T, Ueda K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Izumi N.
  • Journal Title: Cancer. Volume: 15;120(2) Issue: 2 Pages: 229-237
  • DOI: 10.1002/cncr.28384
  • Peer Reviewed
• [Journal Article] Impaired brain activity in cirrhotic patients with minimal hepatic encephalopathy: evaluation by near infrared spectroscopy. (2013)
  • Author(s): Nakanishi H,Asahina Y, Izumi N et al
  • Journal Title: Hepatol Res Volume: in press Issue: 3 Pages: 319-326
  • DOI: 10.1111/hepr.12127
  • Peer Reviewed
• [Journal Article] α-fetoprotein levels afterinterferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C (2013)
  • Author(s): Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nakagawa M, Kakinuma S, Watanabe M,Izumi N
  • Journal Title: Hepatology Volume: (in press) Issue: 4 Pages: 1253-1262
  • DOI: 10.1002/hep.26442
  • Peer Reviewed
• [Journal Article] Guidelines for the Management of Hepatitis C Virus Infection. (2013)
  • Author(s): Asahina Y, Hayashi N, Izumi N, Koike K, Kumada H, Oketani M, Suzuki F, Takikawa H, Tanaka A, Tsubouchi H, Yotsuyanagi H: editors of the Drafting Committee for Hepatitis Management Guidelines.
  • Journal Title: Hepatol Res Volume: 43 Issue: 1 Pages: 1-34
  • DOI: 10.1111/hepr.12020
  • NAID: 130003384472
  • Peer Reviewed
• [Journal Article] Inhibition of hepatocellular carcinoma by PegIFNα2a in patients with chronic hepatitis C: a nationwide multi-center cooperative study. (2013)
  • Author(s): Izumi N, Asahina Y, Kumada H et al
  • Journal Title: J Gastroenterol Volume: 48 Issue: 3 Pages: 382-390
  • DOI: 10.1007/s00535-012-0641-9
  • Peer Reviewed
• [Journal Article] Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type-I interferon-dependent innate immunity (2013)
  • Author(s): Nitta S, Sakamoto N, Nakagawa M, Kakinuma S, Mishima K, Kusano-kitazume A, Kiyohashi K, Murakawa M, Nishimura-Sakurai Y, Azuma S, Tasaka-Fujita M, asahina Y, Yoneyama M, Fujita T, Watanabe M
  • Journal Title: Hepatology Volume: 57 Issue: 1 Pages: 46-58
  • DOI: 10.1002/hep.26017
  • Peer Reviewed
• [Journal Article] Wnt5a Signaling Mediates Biliary Differentiation of Fetal Hepatic Stem/Progenitor Cells (2013)
  • Author(s): Kakinuma S, Kiyohashi K, Kamiya A, Sakamoto N, Nitta S, Yamanaka H, YoshinoK, Fujiki J, Murakawa M, Kusano-Kitazume A, Shimizu H, Okamoto R, Azuma S, Nakagawa M, Asahina Y, Tanimizu N, Kikuchi A, Nakauchi H, and *WatanabeM
  • Journal Title: Hepatology Volume: (in press) Issue: 6 Pages: 2502-2513
  • DOI: 10.1002/hep.26293
  • Peer Reviewed
• [Journal Article] Clinical Characteristics of Patients who Developed Hepatocellular Carcinoma after Hepatitis C Virus Eradication with Interferon Therapy: Current Status in Japan (2013)
  • Author(s): Sato A, SataM, Ikeda K, Kumada T, Izumi N, Asahina Y, Osaki Y, Chayama K, Kaneko S, Sakai A, Onji M, Hiasa Y, Omura T, Ozeki I, Yokosuka O, Shiina S, Itsubo M, Nishiguchi S, Hirano K, Ide T, Sakisaka S, Yamasaki T, Hidaka I, Tanaka M, Kim SR, Ichida T.
  • Journal Title: Internal Medicine Volume: 52 Issue: 24 Pages: 2701-2706
  • DOI: 10.2169/internalmedicine.52.1180
  • NAID: 130003383756
  • ISSN: 0918-2918, 1349-7235
  • Peer Reviewed
• [Journal Article] Noninvasive estimation of fibrosis progression overtime using the FIB-4 index in chronic hepatitis C. (2013)
  • Author(s): Tamaki N, Asahina Y, Izumi N et al
  • Journal Title: J Viral Hepat Volume: 20 Issue: 1 Pages: 72-76
  • DOI: 10.1111/j.1365-2893.2012.01635.x
  • Peer Reviewed
• [Journal Article] Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b. (2013)
  • Author(s): Toyota J, Asahina Y, Kumada H et al
  • Journal Title: J Viral Hepat Volume: 20 Issue: 3 Pages: 167-173
  • DOI: 10.1111/j.1365-2893.2012.01640.x
  • Peer Reviewed
• [Journal Article] Wnt5a signaling mediates biliary differentiation of fetal hepatic stem/progenitor cells (2013)
  • Author(s): Kiyohashi K
  • Journal Title: Hepatology Volume: in press
  • Peer Reviewed
• [Journal Article] α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C (2013)
  • Author(s): Asahina Y
  • Journal Title: Hepatology Volume: in press
  • Peer Reviewed
• [Journal Article] Impaired brain activity in cirrhotic patients with minimal hepatic encephalopathy: evaluation by near infrared spectroscopy (2013)
  • Author(s): Nakanishi H
  • Journal Title: Hepatol Res Volume: in press
  • Peer Reviewed
• [Journal Article] No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations. (2012)
  • Author(s): Sawai H, Asahina Y, Tokunaga K et al
  • Journal Title: BMC Med Genet Volume: 13 Issue: 1 Pages: 47-47
  • DOI: 10.1186/1471-2350-13-47
  • Peer Reviewed
• [Journal Article] Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. (2012)
  • Author(s): Nishida N, Asahina Y, Mizokami M et al
  • Journal Title: PLoS One Volume: 7 Issue: 6 Pages: 1-8
  • DOI: 10.1371/journal.pone.0039175
  • Peer Reviewed
• [Journal Article] Randomized phase IIstudy of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Oeganization PC-01 study) (2012)
  • Author(s): Ozaka M
  • Journal Title: Cancer Chemother Pharmacol Volume: 69 Issue: 5 Pages: 1197-1204
  • DOI: 10.1007/s00280-012-1822-1
  • Peer Reviewed
• [Journal Article] Association of gene expression involving innate immunity and genetic variation in IL28B with antiviral response (2011)
  • Author(s): Asahina Y, Sakamoto N, et al
  • Journal Title: Hepatology Volume: 55(1) Issue: 1 Pages: 20-29
  • DOI: 10.1002/hep.24623
  • Peer Reviewed
• [Presentation] Gene Alterations in TERT promoter, CTNNB1, and TP53 are closely associated with development and prognosis of hepatocellular carcinoma: comprehensive analyses by next generation sequencing technology. (2015)
  • Author(s): Asahina Y, Kawai-Kitahata F, Kaneko S, Nagata H, Goto F, Otani S, Taniguchi M, Murakawa M, Nitta S, Watanabe T, Tasaka-Fujita M, Itsui Y, Nakagawa M, Kakinuma S, Tanaka S, Tanabe M, Enomoto N, Watanabe M.
  • Organizer: he 50th annual meeting of the European association for the study of the liver (EASL The International Liver Congress 2015)
  • Place of Presentation: Vienna, Austria
  • Year and Date: 2015-04-23
• [Presentation] Gene alterations in β-catenin and p53/ cell cycle control pathway are closely associated with development and prognosis of hepatocellular carcinoma: Comprehensive analyses by next generation sequencing technology. (2014)
  • Author(s): Kawai-Kitahata F, Asahina Y, Kaneko S, Nagata H, Goto F, Otani S, Taniguchi M, Murakawa M, Nitta S, Watanabe T, Tasaka-Fujita M, Itsui Y, Nakagawa M, Kakinuma S, Enomoto N, Watanabe M.
  • Organizer: The 65th Annual Meeting of the American Association for the Study of Liver Disease (AASLD The Liver Meeting 2014)
  • Place of Presentation: Boston, USA
  • Year and Date: 2014-11-07 – 2014-11-11
• [Presentation] Matrix Metalloproteinase-14 regulates the maturation of fetal hepatic stem/progenitor cells in mice. (2014)
  • Author(s): Otani S, Kakinuma S, Kamiya A, Goto F, Kaneko S, Azuma S, Asahina Y, Watanabe M.
  • Organizer: The 65th Annual Meeting of the American Association for the Study of Liver Disease (AASLD The Liver Meeting 2014)v
  • Place of Presentation: Boston, USA
  • Year and Date: 2014-11-07 – 2014-11-11
• [Presentation] Impact of host and therapeutic factors and resistant associated variants on response to interferon based- direct acting antiviral treatment in difficult-to-treat chronic hepatitis C patients. (2014)
  • Author(s): Nakagawa M, Asahina Y, Taniguchi M, Watanabe T, Nishimura-Sakurai Y, Itsui Y, Azuma S, Kakinuma S, Tanaka Y, Watanabe M.
  • Organizer: The 65th Annual Meeting of the American Association for the Study of Liver Disease (AASLD The Liver Meeting 2014)
  • Place of Presentation: Boston, USA
  • Year and Date: 2014-11-07 – 2014-11-11
• [Presentation] Expression of IFN/.4 in liver and PBMC is closely associated with higher basal expression of ISGs and impaired induction of IL28B by interferon treatment in chronic hepatitis C non-responder patients. (2014)
  • Author(s): Murakawa M, Asahina Y, Nakagawa M, Sakamoto N, Nitta S, Kawai-Kitahata F, Taniguchi M, Watanabe T, Itsui Y, Kakinuma S, Watanabe M.
  • Organizer: The 65th Annual Meeting of the American Association for the Study of Liver Disease (AASLD The Liver Meeting 2014)
  • Place of Presentation: Boston, USA
  • Year and Date: 2014-11-07 – 2014-11-11
• [Presentation] Emergence or selection of resistant associated variant immediately after initiation of the therapy is predictive for failure of direct acting antiviral therapy: ultra-deep sequencing analyses for serial time points. (2014)
  • Author(s): Watanabe T, Asahina Y, Nakagawa M, Kakinuma S, YItsui Y, Taniguchi T, Murakawa M, Nagata H, Miura M, Maekawa S, Enomoto E, Watanabe M.
  • Organizer: The 65th Annual Meeting of the American Association for the Study of Liver Disease (AASLD The Liver Meeting 2014)
  • Place of Presentation: Boston, USA
  • Year and Date: 2014-11-07 – 2014-11-11
• [Presentation] Clinical outcomes in patients who develop hepatocellular carcinoma after hepatitis C viral eradication by antiviral therapy. (2014)
  • Author(s): Tsuchiya K, Yasui Y, Tamaki N, Suzuki S, Hosokawa T, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Asahina Y, Izumi N.
  • Organizer: The 65th Annual Meeting of the American Association for the Study of Liver Disease (AASLD The Liver Meeting 2014)
  • Place of Presentation: Boston, USA
  • Year and Date: 2014-11-07 – 2014-11-11
• [Presentation] Associations of HLA-DPB1 with CHB infection and HBV related HCC in Asia. (2014)
  • Author(s): Nishida N, Sawai H, Asahina Y, Mizokami M, et al.
  • Organizer: The 65th Annual Meeting of the American Association for the Study of Liver Disease (AASLD The Liver Meeting 2014)
  • Place of Presentation: Boston, USA
  • Year and Date: 2014-11-07 – 2014-11-11
• [Presentation] Impaired IL28B gene induction and expression of IFNλ4 influenced by the polymorphisms near IL28B gene are closely associated with a non-response to interferon in chronic hepatitis C patients. (2014)
  • Author(s): Asahina Y, Murakawa M, NittaS, Itsui Y, Nakagawa M, Azuma S, Kakinuma S, Watanabe M.
  • Organizer: The 49th annual meeting of the European association for the study of the liver (EASL The International Liver Congress 2014)
  • Place of Presentation: London, UK
  • Year and Date: 2014-04-08 – 2014-04-14
• [Presentation] Gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid magnetic resonance imaging and contrast enhanced ultrasonography with sonazoid as part of therapeutic strategies for small nonhypervascular hepatic nodular lesions. (2014)
  • Author(s): Tsuchiya K, Yasui Y, Takada N, Nakakuki S, Matsuda S, Kaneko S, Muraoka M, Yamashita N, Hattori N, Tamaki N, Osaki S, Suzuki T, Hosokawa K, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Asahina Y, Izumi N.
  • Organizer: The 49th annual meeting of the European association for the study of the liver (EASL The International Liver Congress 2014)
  • Place of Presentation: London, UK
  • Year and Date: 2014-04-08 – 2014-04-14
• [Presentation] Serum interleukin-6 levels during treatment correlate with resistance to telaprevir-based triple therapy in chronic hepatitis C (2013)
  • Author(s): Asahina Y, Nakagawa M, Taniguchi M, Kawai F, Fujiki J, Otani T, Yamanaka H, Murakawa M, Nitta S, Kitazume A, Watanabe T, Sakurai Y, Azuma S, Kakinuma S, Watanabe M.
  • Organizer: The 48th annual meeting of the European association for the study of the liver (EASL The International Liver Congress 2013)
  • Place of Presentation: Amusterdam(Netherlands)
• [Presentation] Substitution of amino acid 70/91 in the hepatitis C virus core region affects infectious virus production and cell surface expression of MHC class I. (2013)
  • Author(s): Tasaka-Fujita M, Sugiyama N, Kang W, Murayama A, Asahina Y, Sakamoto N, Wakita T, Shin EC, Kato T.
  • Organizer: The 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD The Liver Meeting 2013)
  • Place of Presentation: Washington DC(USA)
• [Presentation] Impaired IL28B gene induction and expression of IFNλ4 are closely associated with a non-response to interferon-based therapy in chronic hepatitis C patients. (2013)
  • Author(s): Asahina Y, Murakawa M, NittaS, Itsui Y, Nakagawa M, Azuma S, Kakinuma S, Watanabe M.
  • Organizer: The 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD The Liver Meeting 2013)
  • Place of Presentation: Washington DC(USA)
• [Presentation] Serum interleukin-6 levels during treatment correlate with resistance to telaprevir-based triple therapy in chronic hepatitis C (2013)
  • Author(s): Asahina Y
  • Organizer: EASL: The international liver congress 2013
  • Place of Presentation: Amsterdam
• [Presentation] Supression of Alpha-fetoprotein by Interferon Therapy Reduces The Risk of Hepatocarcinogenesis in Patients with Chronic Hepatitis C (2012)
  • Author(s): Asahina Y
  • Organizer: EASL: The international liver congress 2012
  • Place of Presentation: Barelona
• [Presentation] Association of Gene Expression Involving Innate Immunity and IFN Signaling with Genetic Variation in IL28B in Patients with Chronic Hepatitis C. (2012)
  • Author(s): Asahina Y
  • Organizer: The 10th JSH Single Topic Conference
  • Place of Presentation: Tokyo
  • Invited
• [Presentation] HCV-NS4B Protein Binds STING and Blocks the RIG-I Mediated IFN Pathway. (2012)
  • Author(s): Nitta S
  • Organizer: The 10th JSH Single Topic Conference
  • Place of Presentation: Tokyo
• [Presentation] Discovery of N-(morpholine-4-carbonyloxy) amidine compounds as potent inhibitors against hepatitis C virus replication. (2012)
  • Author(s): Akiko Kusano-Kitazume
  • Organizer: The 10th JSH Single Topic Conference
  • Place of Presentation: Tokyo
• [Presentation] Impaired induction of IL28B expression in PBMC is associated with null response to interferon therapy in chronic hepatitis C. (2012)
  • Author(s): Murakawa M
  • Organizer: 19th International Symposium on Hepatitis C Virus and Related Viruses
  • Place of Presentation: Venice
• [Presentation] HCV-NS4B blocks the RIG-I mediated IFN pathway through targeting of STING. (2012)
  • Author(s): Nitta S
  • Organizer: 19th International Symposium on Hepatitis C Virus and Related Viruses
  • Place of Presentation: Venice
• [Presentation] Imparied IL28B gene induction and poor IL28B promoter activity influenced by the IL28B minor allele are closely associated with a null response to interferon in chronic hepatitis C patients. (2012)
  • Author(s): Asahina Y
  • Organizer: AASLD The Liver Meeting 2012
  • Place of Presentation: Boston
• [Presentation] Risk factors for exceeding the Milan criteria following successful radiofrequency ablation in patients with early stage hepatocellular carcinoma: determination of patients requiring early transplantation or new adjuvant therapy (2012)
  • Author(s): Tsuchiya K
  • Organizer: AASLD The Liver Meeting 2012
  • Place of Presentation: Boston
• [Presentation] Reduced organic anion transporter 2 expression is associated with a high risk for hepatocellulare carcinoma in chronic hepatitis C patients: a propensity score-matched study. (2012)
  • Author(s): Yasui Y
  • Organizer: AASLD The Liver Meeting 2012
  • Place of Presentation: Boston
• [Presentation] Antiviral effects and action mechanisms of novel N-(morpholine-4-carbonyloxy) amidine compaunds against hepatitis C virus. (2012)
  • Author(s): Kusano-Kitazume A
  • Organizer: AASLD The Liver Meeting 2012
  • Place of Presentation: Boston
• [Book] 肝癌治療実践のKnack & Pitfalls RFAのoutcome診療ガイドラインに沿った肝癌治療の要点と盲点 (2013)
  • Author(s): 高山忠利、泉並木、朝比奈靖浩
  • Publisher: 文光堂
• [Book] 肝臓病診療 ゴールデンハンドブック 改訂第2版 (2013)
  • Author(s): 泉並木、朝比奈靖浩
  • Publisher: 南江堂
• [Book] 肝炎ウイルスーB型・C型 (2012)
  • Author(s): 熊田博光、朝比奈靖浩
  • Publisher: 医薬ジャーナル社
• [Book] 臨床検査のガイドライン (2012)
  • Author(s): 日本臨床検査医学会ガイドライン作成委員会、朝比奈靖浩
  • Publisher: 株式会社宇宙堂八木書店